Abstract
In adults, acute lymphoblastic leukemia (ALL) remains a disease, a poor prognosis with long-term disease free survival of only 40-45%. Several new targeted therapies are in development for patients with ALL. These include the use of antibody-drug conjugates targeting antigens expressed on the surface of the leukemic blasts, tyrosine kinase inhibitors (TKIs) targeting the Philadelphia chromosome and the newly described Ph-like ALL subgroup, and chimeric antigen receptor (CAR) T-cell therapy. Early results are promising with these approaches, and some of the drugs such as inotuzumab ozogamicin and blinatumomab are in phase III registration trials.
Original language | English (US) |
---|---|
Title of host publication | Targeted Therapy in Translational Cancer Research |
Publisher | Wiley-Blackwell |
Pages | 121-129 |
Number of pages | 9 |
ISBN (Electronic) | 9781118468678 |
ISBN (Print) | 9781118468579 |
DOIs | |
State | Published - Oct 30 2015 |
Keywords
- Acute lymphoblastic leukemia
- Antibody-drug conjugates
- Chimeric antigen receptor
- Ph-like acute lymphoblastic leukemia
- Targeted therapies
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- General Medicine